Literature DB >> 10520034

Platelet c-mpl expression is dysregulated in patients with essential thrombocythaemia but this is not of diagnostic value.

C N Harrison1, R E Gale, F Pezella, A Mire-Sluis, S J MacHin, D C Linch.   

Abstract

Essential thrombocythaemia (ET) can be difficult to discriminate from an occult case of reactive thrombocytosis (RT). Since thrombopoietin (TPO) is the primary regulator of thrombopoiesis, we have investigated whether levels of TPO and/or its receptor, c-mpl, are of value in the differential diagnosis of ET. Plasma TPO levels in patients with ET, RT and other myeloproliferative disorders (MPDs) did not differ significantly from normal controls. However, surface c-mpl expression was significantly reduced in platelets from 18 ET patients, 0-65.5% of controls (P < 0.001). Immunoblots on five of these and five additional patients were consistent with absent or reduced c-mpl protein levels. The surface c-mpl expression results were significantly different from those in eight RT patients (21. 3-95.5%, P = 0.0015), but there was considerable overlap between the two groups and a reduced level was not restricted to ET. Furthermore, c-mpl expression in ET patients was not different from eight patients with other MPDs (0-87.6%, P = 0.06), nor could it differentiate between ET patients with monoclonal and polyclonal haemopoiesis. Although a low or absent c-mpl level is suggestive of a primary rather than a secondary thrombocytosis, it is insufficiently discriminatory to be used as a diagnostic marker for ET.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10520034     DOI: 10.1046/j.1365-2141.1999.01667.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  7 in total

Review 1.  Basic sciences of the myeloproliferative diseases: pathogenic mechanisms of ET and PV.

Authors:  Rosemary E Gale
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

Review 2.  Understanding platelet generation from megakaryocytes: implications for in vitro-derived platelets.

Authors:  Xiuli Sim; Mortimer Poncz; Paul Gadue; Deborah L French
Journal:  Blood       Date:  2016-01-19       Impact factor: 22.113

3.  Mpl expression on megakaryocytes and platelets is dispensable for thrombopoiesis but essential to prevent myeloproliferation.

Authors:  Ashley P Ng; Maria Kauppi; Donald Metcalf; Craig D Hyland; Emma C Josefsson; Marion Lebois; Jian-Guo Zhang; Tracey M Baldwin; Ladina Di Rago; Douglas J Hilton; Warren S Alexander
Journal:  Proc Natl Acad Sci U S A       Date:  2014-04-07       Impact factor: 11.205

4.  JAK2 and MPL protein levels determine TPO-induced megakaryocyte proliferation vs differentiation.

Authors:  Rodolphe Besancenot; Damien Roos-Weil; Carole Tonetti; Hadjer Abdelouahab; Catherine Lacout; Florence Pasquier; Christophe Willekens; Philippe Rameau; Yann Lecluse; Jean-Baptiste Micol; Stefan N Constantinescu; William Vainchenker; Eric Solary; Stéphane Giraudier
Journal:  Blood       Date:  2014-08-20       Impact factor: 22.113

5.  Clinical features of polycythemia vera and essential thrombocythemia in Japan: retrospective analysis of a nationwide survey by the Japanese Elderly Leukemia and Lymphoma Study Group.

Authors:  Kazuo Dan; Takashi Yamada; Yukihiko Kimura; Noriko Usui; Shinichirou Okamoto; Takashi Sugihara; Kazue Takai; Michihiko Masuda; Mayumi Mori
Journal:  Int J Hematol       Date:  2006-06       Impact factor: 2.490

Review 6.  The pathogenesis of chronic myeloproliferative diseases.

Authors:  A Tefferi
Journal:  Int J Hematol       Date:  2001-02       Impact factor: 2.490

7.  TPO/Mpl Studies in Agnogenic Myeloid Metaplasia.

Authors:  Kirugaval C Hemavathy; Kathir Suppiah; Gazala Hashmi; Allan D Novetsky; Jen C Wang
Journal:  Cell Commun Signal       Date:  2005-02-03       Impact factor: 5.712

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.